BCR ‐ABL Tyrosine Kinase Inhibitors Promote Pathological Changes in Dilator Phenotype in the Human Microvasculature

ConclusionIncubating human arterioles with imatinib or nilotinib switches the mediator of FMD from vasoprotective nitric oxide to pro ‐inflammatory H2O2.

Source: Microcirculation - May 11, 2020 Category: Research Authors: Matthew J. Durand, Shelby N. Hader, Alexa Derayunan, Natalya Zinkevich, Jennifer J. McIntosh, Andreas M. Beyer Tags: ORIGINAL RESEARCH Source Type: research